Table 2.
Baseline characteristics at study entry in the groups with known AF, new AF, and no AF
| Known AF (n = 553) | P-value known vs. new AF | New AF (n = 165) | P-value new vs. no AF | No AF (n = 6150) | |
|---|---|---|---|---|---|
| Congestive heart failure, n (%) | 90 (16.2) | <0.001 | 7 (4.2) | <0.001 | 71 (1.2) |
| Hypertension, n (%) | 322 (58.2) | 90 (54.5) | 3136 (51.0) | ||
| Diabetes mellitus, n (%) | 93 (16.8) | 0.015 | 15 (9.1) | 677 (11.0) | |
| Prior stroke/TIA, n (%) | 98 (17.7) | 0.001 | 11 (6.7) | 447 (7.3) | |
| Vascular disease, n (%) | 82 (14.8) | 0.012 | 12 (7.3) | 380 (6.2) | |
| Female gender, n (%) | 201 (36.3) | 0.012 | 78 (47.3) | 0.038 | 3429 (55.7) |
| CHA2DS2-VASc | |||||
| Mean ± SD | 3.8 ± 1.3 | <0.001 | 3.4 ± 1.1 | 3.4 ± 1.0 | |
| Median (IQR) | 4 (2) | 3 (1) | 3 (1) | ||
| OAC treatment, n (%) | 499 (90.2) | <0.001 | 4 (2.4) | 99 (1.6) | |
| Systolic BP, mean ± SD | 136 ± 19.2 | 0.039 | 139 ± 18.3 | ||
| Diastolic BP, mean ± SD | 81 ± 11.5 | 81 ± 10.2 | |||
| NT-proBNP | |||||
| Mean ± SD | 657 ± 843 | <0.001 | 212 ± 317 | ||
| Median (IQR) | 325 (495) | 149 (173) | |||
| Height (cm), mean ± SD | |||||
| All | 172 ± 9.1 | 0.005 | 170 ± 9. | ||
| Women | 165 ± 6.4 | 0.036 | 164 ± 6.1 | ||
| Men | 178 ± 6.8 | 0.050 | 177 ± 6.5 | ||
| Weight (kg), mean ± SD | |||||
| All | 77 ± 14.9 | 0.005 | 74 ± 13.5 | ||
| Women | 71 ± 15.7 | 0.036 | 69 ± 12.1 | ||
| Men | 82 ± 12.3 | 81 ± 11.8 | |||
| BMI (kg/m2), mean ± SD | |||||
| All | 25.9 ± 4.5 | 25.6 ± 3.9 | |||
| Women | 26.2 ± 5.5 | 0.018 | 25.4 ± 4.3 | ||
| Men | 25.7 ± 3.4 | 25.8 ± 3.4 | |||
AF, atrial fibrillation; BP, blood pressure; BMI, body mass index; IQR, interquartile range; NT-proBNP, N-terminal B-type natriuretic peptide; OAC, oral anticoagulation; SD, standard deviation; TIA, transient ischaemic attack.